MONITORED HIGH-DOSE AZATHIOPRINE TREATMENT REDUCES ACUTE REJECTION EPISODES AFTER RENAL TRANSPLANTATION

Abstract

High-dose AZA therapy in a triple-drug regimen, monitored by 6-TGN, will keep myelotoxicity within acceptable limits with the benefit of a reduction in acute rejection episodes.